Ganciclovir: Antiviral Therapy for Congenital Cytomegalovirus
CYTOMEGALOVIRUS (CMV), a member of the herpesvirus family, is the most common virus passed from the mother to the fetus. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 150 children is born with congenital CMV infection.1 Neonates may also acquire CMV during delivery, via blood transfusions, or through breast milk. Both prenatally and perinatally infected infants are at risk for developing short-term effects and long-term sequelae and are candidates for antiviral therapy.2 Each year, approximately 8,000 children suffer permanent disabilities secondary to CMV infection.1
Document Type: Research Article
Publication date: January 1, 2009
- Neonatal Network is no longer available to subscribers on Ingenta Connect. Please go to http://connect.springerpub.com/content/sgrnn to access your online subscription to Neonatal Network.